Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the infectious disease field in the United States. Its product portfolio includes ABT-450, a protease inhibitor that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV); ABT-493, a next-generation protease inhibitor for HCV infection; EDP-239, an NS5A inhibitor for HCV infection; Cyclophilin inhibitor, which are in preclinical development stage for HCV infection treatment; and Nucleotide Polymerase inhibitor program for HCV infection. The company also develops Bicyclolide antibiotic products focuses on mechanisms gram-positive pathogens, including bacteria resistant...
500 Arsenal Street
Watertown, MA 02472
Founded in 1995
Enanta Announces Approval of AbbVie's Viekirax in Japan for Chronic Hepatitis C
Sep 28 15
Enanta Pharmaceuticals, Inc., (ENTA) announced the approval of AbbVie's (ABBV) Viekirax in Japan for the treatment of genotype 1 chronic hepatitis C, and liver diseases such as compensated cirrhosis. It will be a interferon-free and ribavirin-free treatment option for adult patients. Viekirax consists of a two direct-acting antiviral, oral, fixed-dose combination of protease inhibitor paritaprevir/ritonavir with ombitasvir, dosed once daily for 12 weeks. Approximately 1.5 to 2 million people in Japan is living with HCV. Genotype 1 is the most common HCV genotype with 60% to 70% of patients infected and, of those, about 95% are infected with the genotype 1b (GT1b) sub-type. Upon the approval from Japanese Ministry of Health, Labour and Welfare, Enanta expects to earn and receive a $30 million milestone payment in the quarter ending December 31, 2015. AbbVie is responsible for all worldwide development and commercialization of Viekirax and other HCV treatment regimens containing paritaprevir. The approval is supported by the Phase 3 GIFT-I study.
Enanta Pharmaceuticals, Inc. Approves Amendment to Bylaws
Aug 18 15
On August 14, 2015, and effective as of such date, the Board of Directors of Enanta Pharmaceuticals, Inc. amended and restated the company's bylaws primarily (i) to include an exclusive forum bylaw to make the courts in Delaware the exclusive forum for specified legal claims, including disputes with Enanta stockholders and beneficial owners of Enanta common stock and (ii) to require additional information to be disclosed by stockholders proposing director nominees or any other proposal to be brought before a meeting of Enanta stockholders.
Enanta Pharmaceuticals, Inc. Announces Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2015; Provides Royalties Guidance for the Fourth Quarter Ending September 30, 2015
Aug 6 15
Enanta Pharmaceuticals, Inc. announced consolidated earnings results for the third quarter and nine months ended June 30, 2015. For the quarter, the company reported revenue of $11,599,000 compared to $42,051,000 a year ago. Income from operations was $1,703,000 compared to $34,895,000 a year ago. Income before income taxes was $1,990,000 compared to $34,931,000 a year ago. Net income was $2,418,000 or $0.13 per basic and diluted share compared to $50,053,000 or $2.61 per basic and diluted share a year ago.
For the nine months, the company reported revenue of $146,464,000 compared to $45,104,000 a year ago. Income from operations was $120,474,000 compared to $24,311,000 a year ago. Income before income taxes was $121,272,000 compared to $24,358,000 a year ago. Net income was $73,180,000 or $3.80 per basic and diluted share compared to $39,480,000 or $2.06 per basic and diluted share a year ago.
The company expects its royalties in the quarter ending September 30, 2015 to continue to be approximately 3% of such sales.